Literature DB >> 22627098

Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis.

Ko-Ming Lin1, Jing-Chi Lin, Wen-Yi Tseng, Tien-Tsai Cheng.   

Abstract

The B-cell depletion agent rituximab (RTX) is used in lymphoma and rheumatoid arthritis (RA), and there have been several case reports of an RTX-induced reactivation of hepatitis C virus in patients with lymphoma. However, there have been no papers detailing hepatitis C virus reactivation after RTX therapy in a patient with RA. Here we report a case of RTX-induced hepatitis C virus reactivation in a patient with RA. Physicians should be aware that a close follow-up of liver function and viral load is mandatory after RTX therapy in patients with RA and concomitant hepatitis C.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22627098     DOI： 10.1016/j.jmii.2011.12.020

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


  5 in total

Review 1.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

Review 2.  Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis.

Authors:  Lin Li; Xian Jiang; Lixin Fu; Liwen Zhang; Yanyan Feng
Journal:  Clin Exp Med       Date:  2022-04-30       Impact factor: 3.984

3.  Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis.

Authors:  Katrina Wilcox Hagberg; Rebecca Persson; Catherine Vasilakis-Scaramozza; Steve Niemcryk; Michael Peng; Maria Paris; Anders Lindholm; Susan Jick
Journal:  Clin Epidemiol       Date:  2020-02-12       Impact factor: 4.790

Review 4.  B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Authors:  Md Yuzaiful Md Yusof; Edward M Vital; Maya H Buch
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592

Review 5.  Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature.

Authors:  Catharina Korsukewitz; Stephen W Reddel; Amit Bar-Or; Heinz Wiendl
Journal:  Nat Rev Neurol       Date:  2020-07-08       Impact factor: 44.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.